News
ATRA
--
0.00%
--
CAR-T Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | AbbVie Inc., Amgen, Inc., Atara Biotherapeutics, Inc., Autolus Therapeutics PLC., bluebird bio, Celgene, Gilead
Apr 14, 2021 (AB Digital via COMTEX) -- CAR-T is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the...
ABNewswire · 5d ago
Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research
MENLO PARK, Apr 13, 2021 (GLOBE NEWSWIRE via COMTEX) -- MENLO PARK, Calif. and BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a...
GlobeNewswire · 6d ago
Rare Disease Drug Market Aims to Expand at Double-Digit Growth Rate By 2027
Apr 12, 2021 (Market Insight Reports) -- The latest report as Rare Disease Drug Market acknowledges Size, Application Segment, Type, Regional Outlook, Market...
Market Insight Reports · 04/12 18:24
Growth/Differentiation Factor 8 Market Research With Method, Top Companies, Global Development Factors,and Forecast 2027
Market Insight Reports · 04/09 09:22
Nasopharyngeal Cancer Drug Market Size, Share, Growth, Industry Analysis, Global Competitive Analysis, 2021 Worldwide Trends, Business Opportunities and Demand Forecast to 2027
Apr 05, 2021 (The Expresswire) -- Global "Nasopharyngeal Cancer Drug Market" 2021 Industry Research Report is profound investigation by authentic and ebb and...
The Express Wire · 04/05 08:29
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire · 04/02 21:35
Global Growth/Differentiation Factor 8 Market Insights, Overview, Analysis and Forecast 2015-2026
Mar 30, 2021 (Heraldkeepers) -- This report researches the worldwide Growth/Differentiation Factor 8 market size (value) in key regions like United States,...
Heraldkeepers · 03/30 16:44
Growth and Differentiation Factor 8 Global Market Growth, Status and Outlook Research Report 2021
Mar 30, 2021 (Heraldkeepers) -- Product Type Coverage (Market Size & Forecast, Major Company of Product Type...
Heraldkeepers · 03/30 10:23
Viracta Therapeutics is ‘an oncology diamond’: Evercore ISI
Calling the company ‘an oncology diamond,’ Evercore ISI has initiated coverage on Viracta Therapeutics ([[VIRX]] +11.5%) with an outperform rating. Its lead program for the treatment of relapsed/refractory (R/R) EBV+
Seekingalpha · 03/25 15:56
AstraZeneca’s updated data to address integrity issue; Vertex moves to focus list at Citi in today’s analyst action
Updated interim data provided by AstraZeneca (AZN) yesterday from its late-stage COVID-19 vaccine trial in the U.S., should address the data integrity issue, UBS wrote in a note. AstraZeneca ADRs are
Seekingalpha · 03/25 13:00
We're Hopeful That Atara Biotherapeutics (NASDAQ:ATRA) Will Use Its Cash Wisely
Simply Wall St. · 03/21 08:58
Nasopharyngeal Cancer – Pipeline Insight, 2021
Mar 18, 2021 (Heraldkeepers) -- DelveInsight's, "Nasopharyngeal Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 30+ companies...
Heraldkeepers · 03/18 13:43
CAR T Cell Therapy Market Size 2021 by Consumption Volume, Average Price, Revenue, Market Share and Trend to 2025
The Express Wire · 03/17 10:36
Global Anal and Colorectal Cancer Market Insights, Overview, Analysis and Forecast 2021-2026
Mar 17, 2021 (Heraldkeepers) -- Anal cancer occurs in the anus, which is at the end of the gastrointestinal tract. It is different from and less common than...
Heraldkeepers · 03/17 04:32
Global Adoptive Cell Transfer Therapy Market Size, Share, Value, and Competitive Landscape 2024 .
Mar 16, 2021 (Heraldkeepers) -- According to this latest study, the 2021 growth of Adoptive Cell Transfer Therapy will have significant change from previous...
Heraldkeepers · 03/16 13:22
Atara Bio presents Phase 2 tab-cel data in Epstein-Barr virus-driven PTLD
Atara Biotherapeutics (ATRA) announces a combined long-term overall survival ((OS)) analysis from clinical study of tabelecleucel (tab-cel) in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after hematopoiet...
Seekingalpha · 03/15 04:16
Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel(R) Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoim...
BusinessWire · 03/14 20:00
Global Growth or Differentiation Factor Market Insights, Overview, Analysis and Forecast 2021
Mar 10, 2021 (Heraldkeepers) -- Global Growth or Differentiation Factor 8 Market Overview:Global Growth or Differentiation Factor 8 Market Report 2020 comes...
Heraldkeepers · 03/11 02:18
Atara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoim...
BusinessWire · 03/09 21:01
Webull provides a variety of real-time ATRA stock news. You can receive the latest news about Atara Biotherapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATRA
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.